The Government Spent 55 Years Calling Psilocybin Medically Worthless. Now It's Racing to Approve It.

Randy Price got two minutes at the microphone. So did his wife, Jacqueline. Both are Navy veterans, and on September 14, 2026, they sat in a hearing room at FDA headquarters in Silver Spring, Maryland, waiting their turn among roughly 80 public commenters scheduled in two-minute blocks. Randy talked about friends who came home from war and never landed right, and about how little anyone can promise someone walking into a psychedelic-assisted session: “you literally just don’t know how it’s going to turn out.” Jacqueline took the more hopeful position: “if there’s something that’s available that can be helpful, yes, I would say yes.” Same marriage, same war, opposite instincts — a more honest snapshot of where this drug class stands than any press release.

The federal government spent 55 years insisting psilocybin and its chemical relatives had no medical value, and it is now moving faster to approve them than it has moved for almost any other drug class in FDA history.

That’s not a metaphor. It’s the literal regulatory posture. In April 2026, President Trump signed an executive order — after a White House fact sheet framed it as urgent action on “serious mental illness” — directing agencies to speed development of drugs in a class the FDA calls serotonin 2A agonists. Six days later, the FDA handed out three national priority review vouchers: one to Compass Pathways for psilocybin in treatment-resistant depression, one to the Usona Institute for psilocybin in major depressive disorder, one to Transcend Therapeutics for methylone — an MDMA-family compound — in PTSD. Those vouchers can compress an FDA review from ten to twelve months down to as little as one or two. In July, the agency finalized formal clinical-trial guidance for the whole drug class. And in September, it held the public hearing where the Prices testified — a formal step toward building out training, credentialing, and access rules for a therapy that doesn’t exist as an approved product yet.

What a “serotonin 2A agonist” actually does to your brain

Here’s the plain-language version, before the jargon: these drugs work by unlocking your brain’s ability to rewire itself, and the disorienting trip is not a side effect of that — it’s the mechanism.

Now the term. Psilocybin, LSD, and their chemical relatives are called serotonin 2A agonists because they bind tightly to a specific docking site on brain cells — the 5-HT2A receptor — that your brain’s own serotonin barely touches under normal conditions. When a psychedelic locks onto that receptor, cortical neurons briefly go into a state of heightened plasticity: they grow new dendritic branches, form new synaptic connections, and become more responsive to change, the way Ly and colleagues documented in a widely cited 2018 lab study. Researchers describe this as reopening a “critical period” — a window, similar to the one that lets a toddler’s brain absorb language, in which entrenched patterns like a trauma loop, a depressive rut, or a craving circuit become temporarily easier to rewrite. The catch, and it’s a real one: the leading theory holds that the subjective trip — the altered sense of self, the emotional intensity, sometimes the fear — isn’t incidental to that plasticity window. It may be part of how the drug does its work. You can’t easily separate the medicine from the experience of taking it.

That’s promising, and it’s also exactly why these drugs are so hard to study honestly.

What’s genuinely working, and what nobody has proven yet

Early trial data on psilocybin for treatment-resistant depression is real and it’s not nothing — Compass Pathways has reported durable response signals out to six months, enough to justify a rolling New Drug Application. MDMA-family compounds have shown striking numbers in small PTSD cohorts, including trials in which most veteran participants reported meaningful symptom improvement months after dosing. But calibrate that against what an FDA advisory committee said out loud in June 2024, when it voted 10-1 against recommending MDMA-assisted therapy for PTSD: the trials suffered from “functional unblinding,” meaning almost everyone in the room — patient and therapist alike — could tell within an hour who’d gotten the real drug, because the real drug feels unmistakably like something. Reviewers also flagged that a large share of participants had used MDMA recreationally before enrolling, that the therapy itself was so intensive it was hard to separate from the drug’s effect, and that sample sizes across this entire field remain small. Nobody has long-term relapse data at population scale for any of this. The FDA’s new guidance formally acknowledges the unblinding problem and requires sponsors to build trials around it — active placebos, blinding checks, dose-response designs that don’t rely on blinding at all — which is a serious methodological fix, not a dismissal. It’s also an admission that the last decade of trial data was built on a shakier foundation than the headlines suggested.

Nobody has long-term relapse data at population scale for any of this.

If you’re in recovery from a substance use disorder or living with PTSD and you’ve been watching this news hoping it means help is imminent, that caution isn’t a reason to write off the science — it’s the reason to trust it more than the hype cycle around it.

The last time the government did a 180 on this drug class, it cost thirty years

In the early 1960s, Harvard ran an active, federally tolerated psilocybin research program studying mood, personality, and behavior. It collapsed under its own excess — Timothy Leary and Richard Alpert blurred research into personal advocacy so thoroughly that Harvard fired both men in 1963. That scandal, stacked onto a decade of “bad trip” panic, fed directly into the 1970 Controlled Substances Act, which placed psilocybin and LSD in Schedule I — no accepted medical use, high potential for abuse. That classification shut off nearly all clinical psychedelic research in the U.S. for roughly three decades. The molecules never changed. The government’s answer to “does this have medical value” flipped from a hard no to a fast-tracked yes, and the fifty-five years in between are the actual cost of that reversal.

The gate nobody’s mentioning at the ribbon-cutting

Here’s the part that gets flattened every time this story gets covered as a straight win: FDA approval and DEA scheduling are two different federal processes, run by two different agencies, on two different clocks — and psilocybin is still Schedule I today. Compass Pathways’ final NDA submission for COMP360 is on track for the fourth quarter of 2026, with the company targeting a commercial launch in the first half of 2027. But that launch is explicitly “subject to FDA approval and DEA rescheduling,” and rescheduling a Schedule I compound is a separate, unresolved administrative process with its own timeline, its own comment period, and no guaranteed outcome. Even a rescheduled, FDA-approved drug still has to clear state medical boards, insurance formularies, and a workforce that mostly hasn’t been trained to sit in a room for six hours while a patient is dosed — which is precisely what the September hearing was convened to start figuring out. An approval headline is not the same thing as a prescription you can fill.

None of this changes what’s available to you right now. If you’re navigating a substance use disorder or PTSD today, effective, currently approved treatment — medication-assisted treatment, trauma-focused therapy, peer support — still exists, still works for a lot of people, and doesn’t require waiting on a scheduling hearing.

But it’s worth sitting with what Randy Price actually said, because it’s truer than most of the coverage of this story. “You literally just don’t know how it’s going to turn out.” That’s the drug. It’s also the regulatory process now racing to approve it. The honest version of this story isn’t “psychedelics are approved” or “psychedelics are dangerous hype” — it’s that a drug class the government spent five decades treating as contraband with no medical value is now moving through federal review at a speed usually reserved for wartime vaccines, on evidence that is real but thin, toward an implementation gate that is nowhere near closed. Watch the DEA docket as closely as the FDA one. Trust the clinicians and the trial data over whoever’s promising you a timeline.